'Up to Paul now': Galapagos' new CEO Stoffels jumps straight into deal talks, finding a new science chief Lilly, BMS drugs join top TV ad spenders in December as Dupixent stays on top Philips adds even more ventilators to Class I recall caused by faulty sound-muffling foam Biden admin redirected nearly $7B of provider relief to COVID vaccine, therapeutics purchases: report With GSK, Alector has the Big Pharma backing to capitalize on a big moment in Alzheimer's drug development Biogen boosts Aduhelm confirmatory trial amid fight for wider Medicare coverage BioVentrix snatches up MateraCor for a hydrogel-based approach to heart failure Health cost regulator tells Mass General Brigham to clamp down on spending, critiques $2B expansion plan Taysha mulls tweaks to gene therapy trial after subject dies Pfizer in Texas showdown: Court hearing this week will decide if it can assist FDA in providing COVID documents InnovHeart opens the funding valve with $55M to usher mitral system through clinical trials Number of ACOs increases modestly to 483 for 2022, which advocates say should be wake-up call Featured Story | By Kyle LaHucik Galapagos' new CEO, Paul Stoffels, M.D., is ready to jump into acquisition and partnership talks and review new chief science officer candidates as he oversees a much-needed turnaround for the 23-year-old biotech. read more |
| |
|---|
|
Top Stories By Ben Adams Sanofi and Regeneron’s immunology blockbuster Dupixent ended the year nabbing the highest TV ad spend for December. That's nothing new—but the list from real-time TV ad tracker iSpot.tv also turns up some new members and big spending movements. read more By Andrea Park Just as Philips began plotting out its recovery from the Class I ventilator recall it’s been grappling with for the better part of a year, it was hit with yet another curveball. read more By Dave Muoio A new report citing internal documents suggests that HHS spent Congress-allocated relief funds for hospitals and practices on COVID-19 vaccines and therapeutics. The agency said its decision was appropriate because those same resources were provided to hospitals at no cost. read more By Annalee Armstrong Alector is heading into 2022 backed by GlaxoSmithKline, which will allow the immuno-neurology biotech to go after four or five diseases at once—and at a time when neurodegenerative drug development has been catapulted into the spotlight. read more By Angus Liu Biogen plans to power up an FDA-mandated postmarketing study of Alzheimer’s disease drug Aduhelm—a clinical trial that could be the sole revenue source for the controversial medicine for years to come if a Medicare coverage policy is finalized. read more By Conor Hale For an undisclosed amount, the former Fierce 15 winner has bought up MateraCor, a California startup developing a hydrogel injection for strengthening the heart muscle wall. read more By Dave Muoio Massachusetts' largest health system saw its commercial spending growth far outstrip that of other providers in the state from 2014 to 2019, according to an investigation from the Massachusetts Health Policy Commission. read more By Nick Paul Taylor Taysha Gene Therapies is mulling tweaks to its immunosuppression regimen after the first recipient of its gene therapy died. The death overshadowed positive biomarker data on Taysha’s treatment for infantile onset GM2 gangliosidosis, a severe neurodegenerative disease. read more By Kevin Dunleavy Texas federal judge Mark Pittman will conduct a hearing on Friday to consider whether to allow Pfizer to participate in the redaction and release of information about the development of its COVID-19 vaccine, Comirnaty. read more By Andrea Park InnovHeart may not have grown three sizes in one day, but it’s gotten quite a boost from the recent close of its series C funding round. read more By Robert King The number of ACOs in the Medicare Shared Savings Program increased modestly to 483, which advocates say is a major warning sign for the program. read more |
